MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Stock Performance

MDXG stock opened at $6.63 on Wednesday. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $977.04 million, a PE ratio of 12.05 and a beta of 1.74. The business has a 50 day moving average of $7.75 and a 200-day moving average of $7.99. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. As a group, sell-side analysts expect that MiMedx Group will post 0.3 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now directly owns 440,178 shares in the company, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock valued at $1,130,312 over the last ninety days. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On MiMedx Group

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in shares of MiMedx Group by 2.2% during the 4th quarter. Invesco Ltd. now owns 56,565 shares of the company’s stock valued at $544,000 after purchasing an additional 1,226 shares during the period. Rhumbline Advisers grew its holdings in MiMedx Group by 1.4% during the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock valued at $1,346,000 after buying an additional 2,436 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after buying an additional 2,837 shares during the period. IMG Wealth Management Inc. purchased a new stake in shares of MiMedx Group in the fourth quarter worth about $28,000. Finally, SkyView Investment Advisors LLC lifted its holdings in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after buying an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.